Skip to content
OpenCapital
Get started

Gyre Therapeutics, Inc. GYRE Enterprise value

Enterprise value at other companies

Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$12.15B+67.5%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$3.81B-14.5%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$588.13M+55.1%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$543.41M+96.3%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$452.74M+5.3%

Other financials

Income statement

See full
Revenue$22.5M+2.1%
Gross profit$21.3M+0.6%
Operating income-$9.4M-512%
Net income-$8.7M-422%
EPS (diluted)-$0.10—

Balance sheet

See full
Cash & equivalents$37.5M+149%
Total debt$823.0K-48.1%
Total equity$101.3M+48.7%
Total assets$162.0M+24.8%

Cash flow

See full
Operating cash flow$3.2M+2,565%
CapEx$178.0K+45.9%
Free cash flow$3.0M+1,296%

Valuation

See full
Market cap$694.58M-4.7%
P/S5.9×-1.3×

Profitability

See full
Gross margin95.1%-1.1pp
Operating margin-0.1%-10.4pp
Net margin6.3%+3.3pp
FCF margin2.6%—

Returns & leverage

See full
Return on equity8.2%+4.2pp
Debt / equity0×0.0×
Current ratio4.6×+1.0×

Where this comes from

Calculated from Gyre Therapeutics, Inc.’s reported figures.

$636.5Mmarket cap+$823.0Ktotal debt−$37.5Mcash and equivalents=$599.78M

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s enterprise value?
Gyre Therapeutics, Inc. (GYRE) reported enterprise value of $599.78M in Q1 2026.
How has Gyre Therapeutics, Inc.'s enterprise value changed year-over-year?
Gyre Therapeutics, Inc.'s enterprise value decreased by 15.4% year-over-year, from $709.23M to $599.78M.
What is the long-term trend for Gyre Therapeutics, Inc.'s enterprise value?
Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s enterprise value has grown at a -42.3% compound annual growth rate (CAGR), from $1.93B to $643.98M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.